To ascertain the effects of chronic renal failure on the pharmacokinetics of 1 R-cis 1ЈR-cis atracurium besylate (a stereoisomer, designated 51W89), we gave a bolus dose of 0.1 mg kg 91 (2 ED 95 ) to 17 patients with end-stage renal failure and to 15 patients with normal renal function undergoing elective surgery. All patients received thiopentone, fentanyl and midazolam i.v. and 70 % nitrous oxide in oxygen. Blood samples were obtained over 8 h and plasma analysed for 51W89 and laudanosine concentration, using high pressure liquid chromatography. A two-compartment model was fitted to the 51W89 plasma concentration data using the NONMEM program, to estimate pharmacokinetic variables and to determine the influence of renal failure, age, weight and sex. Clearance of 51W89 was found to be reduced by 13 % in renal failure. The typical value of β ½ % was 4.2 min longer in renal failure than in the healthy patients (34.2 vs 30.0 min, P : 0.005). In the healthy patients, clearance of 51W89 was greater in males, but it decreased with increasing age by approximately 1.5 ml min 91 yr
Atracurium besylate is a benzylisoquinolinium nondepolarizing neuromuscular blocking agent, with a kinetic profile which is unchanged by renal impairment [1, 2] . It is therefore a popular agent to use in patients with chronic renal failure, because the duration of its clinical effect is unchanged [1, 3] . Clearance of atracurium is unaltered because of the safety net of Hofmann elimination [2, 4] , whereby spontaneous breakdown of the drug occurs at body temperature and pH.
Laudanosine is a product of this metabolic pathway. In animal studies, laudanosine has been shown to stimulate abnormal electroencephalographic activity and epileptic convulsions [5, 6] , although this has not been reported in humans.
Laudanosine is cleared in part by the kidney [7] , and probably also by the liver [8] .
The atracurium molecule has four chiral centres; 10 distinct stereoisomers are found in the commercial preparation [9] . Several of these compounds have undergone laboratory investigation and one (1R-cis 1ЈR-cis atracurium besylate, designated 51W89) is currently undergoing phase III clinical trials. This isomer is more potent than atracurium [10, 11] ; animal studies have shown it to be more selective for the postsynaptic nicotinic receptor, with less autonomic effect [12] .
We examined the pharmacokinetics of 51W89 in health and chronic renal failure and measured the plasma concentration of its metabolite, laudanosine.
Patients and methods
After approval by the Committee on Safety of Medicines and the hospital Ethics Committee, we obtained written informed consent from 32 patients to take part in the study; 17 with end-stage chronic renal failure undergoing regular dialysis and 15 healthy patients. The pharmacodynamics of 51W89 in these patients have been reported previously [13] . The renal failure patients were not undergoing renal transplantation; they were scheduled for either dialysis access procedures (n : 14), renal transplant nephrectomy (n : 2) or femoropopliteal bypass (n : 1). The healthy patients were undergoing elective surgery, for example, inguinal hernia repair or laparoscopic cholecystectomy.
Patients were excluded if there was a history, or physical signs, of any neuromuscular disorder, obesity, asthma, cardiac failure or liver disease, and also if they were receiving drugs thought to interfere with neuromuscular transmission, including anticonvulsants, aminoglycoside antibiotics, antihistamines, antidepressants and anti-arrhythmics. None of the females was pregnant or breast feeding.
Before operation, haemoglobin, blood glucose, plasma urea and electrolyte concentrations were measured. Liver function tests were also carried out. All patients were weighed and their heights recorded. The ideal weight for each patient was obtained from published insurance tables [14] . to prevent degradation of the isomer. The acidified plasma was kept on ice and deep frozen within 30 min.
Plasma samples were analysed using a gradient method of high pressure liquid chromatography (HPLC) with fluorescence detection; the method used was similar to that reported for atracurium [15] . The concentration of 51W89 was expressed as that of the bis-cation, which has 75 % of the mass of the dibenzene sulphonate salt (as has been used to express the dose of atracurium). The accuracy of the analysis was assessed by the use of standards of 51W89 15-1500 ng ml 91 and laudanosine 15-750 ng ml 91 in pooled bank human plasma. The coefficient of variation of the analysis for 51W89 varied from 14 % at the lower limit of detection to 10 % at 1500 ng ml
91
, and that for laudanosine from 10 % at the lower limit of detection to 4 % at 750 ng ml
. On the day after surgery, each patient was examined clinically and blood was again obtained for chemical and haematological analyses.
A two-compartment model was fitted to the plasma concentrations of 51W89, using the NONMEM (nonlinear mixed effects model) program [16] . Unlike traditional pharmacokinetic analysis where the data from each individual are analysed separately, this method deals with all patients simultaneously. Variables are not derived for each individual; instead, a population mean for each pharmacokinetic variable is derived, together with an estimate of the random variability of that variable within the population.
In addition to defining a population mean for each variable, it is also possible to determine the influence of such factors as age, weight, sex and the presence of renal failure on each variable. The statistical significance of such factors is assessed by the change which their inclusion in the model makes to the goodness of fit of the model to the data, defined by the objective function (actually, 2 log likelihood of the model).
The model was characterized in terms of central volume of distribution (V1) and the volume of the peripheral compartment (V2), plasma clearance (Cl) and intercompartmental clearance (Q) (which is the product of the central volume of distribution V1 and the rate constant for transfer from the central to the peripheral compartment). This set of four variables completely defines a basic two-compartment model. In order to determine the distribution ( ) T α ½ and elimination ( ) T β ½ half-lives, additional runs were performed using alternative variables.
Mean plasma laudanosine concentrations in each group at each time were compared using the MannWhitney U test.
Results
All patients completed the study. The physical characteristics of the two groups were similar (table 1). The high plasma creatinine concentrations in the renal failure group are typical of patients in a dialysis programme.
A semi-logarithmic plot of mean (SD) plasma concentrations of 51W89 vs time for each group is shown in figure 1 . 51W89 was not detectable in plasma after 150 min. A linear plot of laudanosine concentrations vs time is shown in figure 2 . Mean laudanosine concentrations in the healthy group were significantly lower than in the renal failure patients from 30 to 240 min (P : 0.05); the plasma laudanosine concentration was above the lower limit of detection in only one healthy patient at 480 min.
A two-compartrment model was fitted to the plasma 51W89 data and plots of predicted vs observed concentrations, and of weighted residuals vs predicted plasma concentrations, suggested the model was adequate. Normalization of volume terms for body weight (thus expressing volumes in units of ml kg 91 and Cl in ml min 91 kg
91
) worsened the fit of the model, and their volume terms are therefore presented throughout without weight correction.
When the effect of renal failure was examined similarly, fitting models of the form, for example: 3 5 renal function. Cl = + ⌰ ⌰ where renal function has a value of 1 or 0, an apparently significant decrease in the objective function was found for the effects of renal function on Cl and on V1. When further variables were added to test for the simultaneous effect of renal function on, for example, both Cl and V1, the fit was not improved further than when renal function was allowed to influence Cl alone. This information is given in detail in table 2.
Pharmacokinetic variables for the optimal model, including the effect of renal function on Cl, are given in table 3.
The distribution and elimination half-lives (T α ½ and ) T β ½ for the healthy and renal failure groups are given in table 4. There was no difference between the groups in the distribution half-life ( ) T α ½ The typical value of T β ½ was 4.2 min longer in renal failure than in healthy patients (P : 0.005).
Consideration of the effect of weight, ideal body weight, age and sex in the healthy patients was undertaken by allowing each individual characteristic, in turn, to influence Cl. A highly significant effect was found for sex (a reduction in objective function of 11.3), and minor effects for weight and ideal body weight (reductions of 6.4 and 5.5). Combination of sex and age produced a further slight improvement (total reduction in objective function of 17.2), but incorporation of weight terms gave no further improvement. In the renal failure group, no significant effect on Cl was found for weight, ideal weight, age or sex. The optimal model for Cl in the healthy group was: 
Discussion
In common with attracurium, estimation of the pharmacokinetic variables of 51W89 is complicated by the problem of spontaneous peripheral degradation of the drug outside the plasma. Standard pharmacokinetic methods assume that all of the drug is eliminated from a central, homogeneous compartment into which the drug is administered. While attempts have been made to allow for this by performing a simultaneous in vitro experiment [17] , this was not done here. A standard compartment model, embodied in the NONMEM program, was applied to provide objective data reduction within a context which would allow the delineation of the factors affecting drug disposition. The mean clearance rate of 51W89 (293 ml min 91 in health) was found to be lower than that of atracurium (372 ml min 91 ), using a similar neurolept anaesthetic technique [18] , but the central volume of distribution of the two drugs was similar (4520 ml for 51W89; 3940 ml for atracurium). It is known that differences in anaesthetic technique may alter the pharmacokinetic variables of atracurium; for example, patients receiving isoflurane were reported to have higher rates of clearance than patients receiving halothane or midazolam [18] , but this would not explain the difference reported here.
The variables derived for 51W89 were similar to those obtained for a combination of all of the cis-cis isomers together, analysed using a stereospecific analysis after a dose of atracurium; mean clearance was reported as 5.3 (SEM 0.4) ml kg 91 min
91
, with a mean central volume of distribution of 60.2 (11.9) ml kg 91 and a mean total volume of distribution of 154.2 (12.7) ml kg 91 [19] . We found a highly significant difference in mean clearance of 51W89 between healthy patients (293 ml min
) and those with end-stage renal failure (254 ml min 91 ) (P : 0.005); this amounts to a reduction of approximately 13 %. It contrasts with atracurium, where clearance was similar in the two groups [1, 2] . It may be that 51W89 undergoes less Hofmann elimination than atracurium, and conversely urinary excretion of this isomer may be greater. These pharmacokinetic differences confirm the findings of a pharmacodynamic study of the recovery characteristics of 51W89 0.1 mg kg 91 in healthy and renal failure patients. The mean values for 75 % and 90 % recovery of T1/T0 and the recovery index (25-75 % Tl/T0) were longer in the renal failure patients, although the differences did not reach statistical significance [13] .
Age and sex also seem to affect the clearance of 51W89 in healthy patients; older patients had a reduced clearance and males had a greater clearance. This effect was not observed in patients with chronic renal failure and may be a reflection of the effect of these factors on renal function. Such an effect of age on the pharmacokinetics of atracurium is now well accepted [15, 18, 20] . The effect of sex found in the present study is similar to a single previous report [18] , but remains unexplained and requires further confirmation.
Plasma concentrations of laudanosine observed after administration of 51W89 are much lower than those after an equipotent dose of atracurium. After atracurium 0.5 mg kg
, the mean peak plasma laudanosine concentration in healthy patients was between 200 and 300 ng ml
, and between 300 and 400 ng ml 91 in chronic renal failure: in each group, the peak concentration occurred within 10 min of the dose of atracurium [7] . The mean peak plasma laudanosine concentration after 51W89 0.1 mg kg 91 was 23.1 ng ml 91 at 4 min in the healthy group and 31 ng ml 91 at 150 min in the renal failure group; these values are one-tenth of those seen after approximately four times the mass of atracurium. This adds further weight to the suggestion that 51W89 is less susceptible to Hofmann elimination than atracurium.
The delay in peak plasma laudanosine in the renal failure group suggests that the source of much of this laudanosine may be another metabolite, such as the product of ester hydrolysis, monoquaternary alcohol, which is also broken down to laudanosine [2] . The degree of ester hydrolysis may be increased in the renal failure group, in whom the absence of renal clearance increases the amount available for breakdown in plasma. Plasma laudanosine concentrations were significantly higher in the renal failure group from 30 to 240 min (P : 0.05); at 480 min the concentration of laudanosine in the renal failure group was higher than that in the single healthy patient in whom laudanosine remained detectable.
The early peak in plasma laudanosine concentration after a bolus of atracurium may result from the formation of laudanosine in the ampoule [15] or rapid metabolism of other shorter lived isomers [21] . We observed less prominent peaks in plasma laudanosine concentration after 51W89 than those observed after atracurium, and this strengthens the hypothesis that the short-lived isomers which exist in a solution of atracurium are responsible for the early peak in the laudanosine concentration.
